HK Stock MarketDetailed Quotes

02566 JIUYUAN GENE

Watchlist
  • 7.420
  • -0.100-1.33%
Market Closed Dec 13 16:08 CST
1.82BMarket Cap12.90P/E (TTM)

About JIUYUAN GENE Company

Established in 1993, we are a Chinese biopharmaceutical company headquartered in Zhejiang Province. We have over 30 years of experience in R&D, production and commercialization of biopharmaceuticals and medical devices. We focus on four rapidly growing treatment areas: orthopedics, metabolic diseases, oncology, and hematology. According to Insight Consultancy data, these four treatment areas together accounted for 51.5% of China's total pharmaceutical sales in 2023, far superior to the overall performance of the Chinese pharmaceutical industry from 2018 to 2023, and the relevant trend is expected to continue in the near future. As of the last practical date, we have established a diversified product portfolio around these treatment fields, including eight marketed products (including China's first recombinant human bone morphogenesis protein-2 (“rhBMP-2”) bone repair material bone guidance) and more than 10 products under development (including China's first simeglutide biosimilar JY29-2, which received IND approval and submitted an NDA application). The first step in our strategy is to identify treatment targets with market potential in the areas we focus on. After confirming the target, we will use China's mature R&D platform, production capacity, and sales and distribution network to develop China's innovative and first imitation products. Our marketed product portfolio includes a pharmaceutical device combination, two biological products, and five chemicals in the orthopedic, oncology and hematology fields. Among them, in 2023, we have several products that maintain competitive positions in their respective product categories in terms of market share measured by revenue. Among our marketed products, three are the first domestically produced products approved for commercialization in China in their respective product categories. Among them, the most notable one is our pharmaceutical combination product bone optimization. According to the Insight Consultation data, it is the first bone repair material containing rhBMP-2 approved for sale in China, ranking first in terms of sales revenue in the 2023 Chinese bone repair materials market. We are aware that bone conduction has excellent prospects for development, so we acquired bone guide from Hangzhou Huadong Pharmaceutical Group Co., Ltd. in 2010, and most of the revenue during the track record period came from this product. For details of this transaction, please refer to “Business — Our Products — Our Listed Products — Orthopedic Products”. According to the same source of information, our two tumor and blood products, gemripene and geperine, are the first domestically produced and commercialized generic biological products or small molecule generic drugs in their various drug classes in China. The revenue generated by all of our listed products accounted for 87.6%, 93.8%, 91.5% and 87.9% of our total revenue for the year ended December 31, 2021, 2022, and 2023, and the six months ended June 30, 2024, respectively.

Company Profile

Symbol02566
Company NameJIUYUAN GENE
ISINCNE100006KF0
Listing DateNov 28, 2024
Issue Price12.42
Shares Offered45.40M share(s)
FoundedDec 31, 1993
Registered AddressChina
Chairmanhang fu
Secretaryxiuheyongya huang
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 23, No. 8 Baiyang Street, Qiantang District, Hangzhou, Zhejiang, China
Head Office and Principal Place of Business46th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees1467
MarketHong Kong motherboard
Phone(0571)86910099
Fax(0571)86911688
Emailoffice@china-gene.com
Business Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a Chinese company mainly engaged in genetic drug research and development. The company's main business is R&D, production and sales of biopharmaceuticals and related medical devices. The company's main products include bone repair materials, imitation enoxaparin sodium, human granulocyte stimulating factor, and injectable interleukin. The company's products are mainly used to treat orthopedic, oncology and hematological diseases. The company mainly operates in domestic and overseas markets.

Company Executives

  • Name
  • Position
  • Salary
  • hang fu
  • Chairman of the Board, Executive Director, General Manager, Nomination Committee Members, Authorized Representative
  • 2.47M
  • wei zhou
  • Executive Director, Deputy General Manager, General Manager of Pharmaceutical Services, Remuneration Committee Members
  • 2.02M
  • honglan ma
  • Non-executive Directors
  • --
  • shihang wu
  • Non-executive Directors
  • --
  • Albert Esteve Cruella
  • Non-executive Directors
  • --
  • junjie fei
  • Non-executive Directors
  • --
  • zhihui zhou
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members
  • 15.00K
  • meiyi he
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
  • 15.00K
  • demin zhou
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 15.00K
  • jiancai ye
  • Chairman of the Supervisory Board
  • 77.00K
  • feihu xu
  • Auditors
  • 100.00K
  • fei zhao
  • Employee Representative Supervisor
  • 39.00K
  • handong sun
  • Deputy General Manager, Director of R&D Center
  • --
  • hui li
  • Deputy General Manager, Production Center Director
  • --
  • xiu huang
  • Joint Company Secretary, Board Secretary
  • 914.00K
  • yanmei yang
  • Chief Financial Officer
  • --
  • yongya he
  • Joint Company Secretary, Authorized Representative
  • --
Trending HK Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks

Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.